/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
In this report, Intuitive Surgical, Intuitive, the Company, we, us, and our refer to Intuitive Surgical, Inc. and its wholly and majority-owned subsidiaries. Product and brand names and logos, including Intuitive, da Vinci, and Ion, are trademarks or registered trademarks of Intuitive Surgical, Inc. or one of its subsidiaries or of their respective owners.
$369.25
$7.61 (-2.02%)
EOD Sep 1, 2026
29.27% operating margin is above average. ROIC at 14.52%.
Revenue grew 20.5%, still solid.
At 42x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
42.4x earnings, 40.9x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$11.03B
▲ +20.5% YoY
Net Income (TTM)
$3.14B
▲ +23.0% YoY
Op. Margin
31.28%
▲ +1.1pp YoY
ROIC
15.89%
▲ +1.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$3.22B
▲ +91.0% YoY
Op. Cash Flow (TTM)
$3.71B
▲ +25.5% YoY
Net Debt
-$5.22B
Net Cash Position
Cash & Equiv.
$5.22B
5Y CAGR: +18.2%
5Y CAGR: +16.9%
Continue Research
SourceComputed from the 10-Q filed 21 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 22 Jul 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 42.4 and a price-to-free-cash-flow of 40.9, Intuitive Surgical (ISRG) trades above a two-stage DCF intrinsic value of about $317.13 per share, so at $369.25 the stock looks overvalued (14.1% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Intuitive Surgical scores 81/100 on Intrinsiqq's quality scorecard (a high-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $317.13 per share for ISRG, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $237.85. At today's $369.25, that puts the stock about 14.1% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Intuitive Surgical scores 81 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a high-quality business on these measures. Recent fundamentals include a 31.3% operating margin and a 15.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. ISRG currently trades above its estimated intrinsic value and scores 81/100 on quality (high-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.